Methods of treating traumatic encephalopathy syndrome

Rho kinase inhibitors, particularly fasudil, offer a promising treatment for Traumatic Encephalopathy Syndrome by enhancing cognitive and neurobehavioral functions in patients with repetitive head trauma, effectively addressing the lack of effective therapies for TES by improving MMSE scores and reducing symptom severity.

WO2024238620A1PCT designated stage expired Publication Date: 2024-11-21WOOLSEY PHARMACEUTICALS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/029409
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current therapeutic approaches are ineffective for treating Traumatic Encephalopathy Syndrome (TES), a condition associated with repetitive brain trauma, leading to cognitive and neurobehavioral impairments, with no disease-modifying treatments available.

Method used

Administration of a rho kinase inhibitor, specifically an isoquinoline derivative like fasudil, to patients with a history of repetitive head impacts, which improves cognitive and neurobehavioral functions by reducing symptom severity and delaying progression of TES symptoms.

Benefits of technology

The treatment with rho kinase inhibitors, such as fasudil, leads to significant improvements in cognitive function, as measured by MMSE scores, and alleviates neurobehavioral symptoms like aggression and depression, with improved MMSE scores ranging from 5 to 10 points, and reduced symptom progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000007_0001
    Figure IMGF000007_0001
Patent Text Reader

Abstract

Disclosed is a method of treating traumatic encephalopathy syndrome (TES) in a patient in need thereof by administering a therapeutically effective amount of a rho-kinase inhibitor. In one embodiment, the rho-kinase inhibitor is fasudil.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • 4-haloisoquinoline derivative and drug containing the same

    US20070088021A1

  • Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof

    US20080194581A1

  • Isoquinolin-3-yl carboxamides and preparation and use thereof

    US20220332698A1

  • Oral formulations of fasudil with ion exchange resin

    US20230330101A1

  • Methods of treating proteinopathies

    WO2022015365A1